Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation

Clinical Breast Cancer

Volumn 17, Issue 5, 2017, Pages 350-355.e4

  Henry, N Lynn ^a   Speth, Kelly ^a   Lintermans, Anneleen ^b   Kidwell, Kelley M ^a   Carlson, Rachel ^a   Hayes, Daniel F ^a   Neven, Patrick ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Body mass index; Grip strength; Noncontinuation; Pain; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDY; SURVIVAL; BREAST TUMOR; CHEMICALLY INDUCED; COMPLICATION; FOLLOW UP; HAND STRENGTH; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HAND STRENGTH; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS;

EID: 85016501800     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2017.03.002     Document Type: Article

References (22)

1. Burstein, H.J., Prestrud, A.A., Seidenfeld, J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28 (2010), 3784–3796.
2. Dowsett, M., Cuzick, J., Ingle, J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28 (2010), 509–518.
3. Henry, N.L., Azzouz, F., Desta, Z., et al. Predictors of aromatase inhibitor discontinuation due to treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30 (2012), 936–942.
4. Chirgwin, J.H., Giobbie-Hurder, A., Coates, A.S., et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34 (2016), 2452–2459.
5. Kadakia, K.C., Snyder, C.F., Kidwell, K.M., et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist 21 (2016), 539–546.
6. Hershman, D.L., Shao, T., Kushi, L.H., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126 (2011), 529–537.
7. Crew, K.D., Greenlee, H., Capodice, J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25 (2007), 3877–3883.
8. Mao, J.J., Stricker, C., Bruner, D., et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115 (2009), 3631–3639.
9. Sestak, I., Cuzick, J., Sapunar, F., et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9 (2008), 866–872.
10. Morales, L., Pans, S., Verschueren, K., et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26 (2008), 3147–3152.
11. Lintermans, A., Van Calster, B., Van Hoydonck, M., et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22 (2011), 1763–1769.
12. Lintermans, A., Van Asten, K., Wildiers, H., et al. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146 (2014), 109–116.
13. Horne, R., The Medication Adherence Report Scale. 2004, University of Brighton, Brighton, UK.
14. Burstein, H.J., Temin, S., Anderson, H., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline focused update. J Clin Oncol 32 (2014), 2255–2269.
15. Burstein, H.J., Lacchetti, C., Anderson, H., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline update on ovarian suppression. J Clin Oncol 34 (2016), 1689–1701.
16. Briot, K., Tubiana-Hulin, M., Bastit, L., Kloos, I., Roux, C., Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120 (2010), 127–134.
17. Crew, K.D., Capodice, J.L., Greenlee, H., et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28 (2010), 1154–1160.
18. Irwin, M.L., Cartmel, B., Gross, C.P., et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33 (2015), 1104–1111.
19. Henry, N.L., Banerjee, M., Wicha, M., et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117 (2011), 5469–5475.
20. Neven, P., Markopoulos, C., Tanner, M.M.E., et al. The impact of educational materials on compliance and persistence with adjuvant aromatase inhibitors: 2 year follow-up and final results from the CARIATIDE study. Cancer Res, 71(suppl 24), 2011 abstract P5-16-02.
21. Hadji, P., Blettner, M., Harbeck, N., et al. The Patient's Anastrozole Compliance to Therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24 (2013), 1505–1512.
22. Yu, K.D., Zhou, Y., Liu, G.Y., et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 134 (2012), 307–313.